Mabwell (02493.HK) Commences Hong Kong IPO, Secures US$53 Million from 6 Cornerstone Investors

Newtimespace News: Mabwell (Shanghai) Bioscience Co., Ltd. (02493.HK) is conducting its Hong Kong public offering from April 20 to April 23, 2026.
The global offering comprises approximately 47,130,200 H shares, including 4,713,200 shares for the Hong Kong public offering (subject to reallocation) and 42,417,000 shares for the international offering (subject to reallocation). The offer price is expected to be between HK$27.64 and HK$30.71 per share. Trading will be in board lots of 200 shares, with an entry fee of HK$6,203.95 (including brokerage commission, SFC transaction levy, HKEX trading fee and FRC transaction levy). Trading is expected to commence on the Main Board of the Hong Kong Stock Exchange on April 28.
The company has secured 6 cornerstone investors, with total subscriptions of US$53 million based on the mid-point of the offer price range at HK$29.18 per share. The cornerstone investors will subscribe for approximately 14.23 million shares。

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.